Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Cemex SAB ( (CX) ) has issued an update.
Cemex announced the payment of the third installment of its cash dividend, totaling USD $32.5 million, as approved during its Ordinary General Shareholders’ Meeting on March 25, 2025. The dividend will be distributed to registered holders of Series A and B shares, CPOs, and ADSs as of December 15, 2025, with payments scheduled for December 16, 2025, in Mexican pesos and December 23, 2025, for ADS holders. This dividend, sourced from Cemex’s Net Tax Profit Account as of December 31, 2013, will not be subject to tax withholding, potentially benefiting shareholders by maximizing their returns.
The most recent analyst rating on (CX) stock is a Hold with a $11.25 price target. To see the full list of analyst forecasts on Cemex SAB stock, see the CX Stock Forecast page.
Spark’s Take on CX Stock
According to Spark, TipRanks’ AI Analyst, CX is a Outperform.
Cemex SAB’s overall stock score is driven by strong financial performance and positive earnings call sentiment, highlighting significant EBITDA growth and cost efficiencies. Technical analysis supports a bullish trend, while valuation remains reasonable. The combination of these factors positions Cemex SAB as a solid investment opportunity in the construction materials industry.
To see Spark’s full report on CX stock, click here.
More about Cemex SAB
Cemex, S.A.B. de C.V. is a leading global building materials company that produces, distributes, and sells cement, ready-mix concrete, and aggregates. The company primarily focuses on the construction industry and operates in various international markets.
Average Trading Volume: 8,715,986
Technical Sentiment Signal: Buy
Current Market Cap: $16.59B
Learn more about CX stock on TipRanks’ Stock Analysis page.

